← Eichor
Study identifier: NCT04062565 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH

Condition: Pulmonary Arterial Hypertension  ·  Sponsor: University of Arizona

PhasePhase 3
Planned participants20
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to determine if there is a greater effect to patients with advanced pulmonary arterial hypertension (PAH) by using a combination of two drugs, Treprostinil and Riociquat versus Treprostinil alone

This description comes directly from the study's public registry record.

Talk to the study team

Valerie Boss, MS  ·  520-626-8305  ·  vbloss@email.arizona.edu

Always discuss trial participation with your own doctor first.

Locations (1)

University of ArizonaTucson, Arizona, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04062565